Optimal therapy for desmoid tumors: current options and challenges for the future

References

• Müller J. Ueber den feinern Bau und die Formen der krankhaften Geschwülste [Internet]. Reimer G; Berlin, Germany: 1838
   Google Scholar
• Escobar C, Munker R, Thomas JO, et al. Update on desmoid tumors. Ann Oncol 2012;23(3):562-9
   PubMed Web of Science ®Google Scholar
• Eastley N, Aujla R, Silk R, et al. Extra-abdominal desmoid fibromatosis–a sarcoma unit review of practice, long term recurrence rates and survival. Eur J Surg Oncol 2014;40(9):1125-30
   PubMed Web of Science ®Google Scholar
• Van Broekhoven DLM, Grünhagen DJ, den Bakker MA, et al. Time trends in the incidence and treatment of extra-abdominal and abdominal aggressive fibromatosis: a population-based study. Ann Surg Oncol 2015;22(9):2817-23
   PubMed Web of Science ®Google Scholar
• De Bree E, Dimitriadis E, Giannikaki E, et al. A giant pregnancy-associated intra-abdominal desmoid tumour: not necessarily a contraindication for subsequent pregnancy. World J Surg Oncol 2013;11:277
   PubMed Web of Science ®Google Scholar
• Bouchikh M, Arame A, Riquet M, Le Pimpec-Barthes F. Cardiac failure due to a giant desmoid tumour of the posterior mediastinum. Eur J Cardiothorac Surg 2013;44(6):1137-9
   PubMed Web of Science ®Google Scholar
• Chu KF, Samara MS, Laver N, Wein RO. A rare presentation of a large extra-abdominal desmoid tumor of the posterior neck and back. Am J Otolaryngol 2013;34(6):727-30
   PubMed Web of Science ®Google Scholar
• Bonvalot S, Ternès N, Fiore M, et al. Spontaneous regression of primary abdominal wall desmoid tumors: more common than previously thought. Ann Surg Oncol 2013;20(13):4096-102
   PubMed Web of Science ®Google Scholar
• Colombo C, Miceli R, Le Péchoux C, et al. Sporadic extra abdominal wall desmoid-type fibromatosis: surgical resection can be safely limited to a minority of patients. Eur J Cancer 2015;51(2):186-92
   PubMed Web of Science ®Google Scholar
• Leithner A, Gapp M, Radl R, et al. Immunohistochemical analysis of desmoid tumours. J Clin Pathol 2005;58(11):1152-6
   PubMed Web of Science ®Google Scholar
• Jia C, Tian B, Dai C, et al. Idiopathic desmoid-type fibromatosis of the pancreatic head: case report and literature review. World J Surg Oncol 2014;12:103
   PubMed Web of Science ®Google Scholar
• Li Destri G, Ferraro MJ, Calabrini M, et al. Desmoid-type fibromatosis of the mesentery: report of a sporadic case with emphasis on differential diagnostic problems. Case Rep Med 2014;2014:850180
   Google Scholar
• Woltsche N, Gilg MM, Fraissler L, et al. Is wide resection obsolete for desmoid tumors in children and adolescents? evaluation of histological margins, immunohistochemical markers, and review of literature. Pediatr Hematol 2015;32(1):60-9
   PubMed Web of Science ®Google Scholar
• Poon R, Smits R, Li C, et al. Cyclooxygenase-two (COX-2) modulates proliferation in aggressive fibromatosis (desmoid tumor). Oncogene 2001;20(4):451-60
   PubMed Web of Science ®Google Scholar
• Mignemi NA, Itani DM, Fasig JH, et al. Signal transduction pathway analysis in desmoid-type fibromatosis: transforming growth factor-beta, COX2 and sex steroid receptors. Cancer Sci 2012;103(12):2173-80
   PubMed Web of Science ®Google Scholar
• Colombo C, Foo WC, Whiting D, et al. FAP-related desmoid tumors: a series of 44 patients evaluated in a cancer referral center. Histol Histopathol 2012;27(5):641-9
   PubMed Web of Science ®Google Scholar
• Alman BA, Goldberg MJ, Naber SP, et al. Aggressive fibromatosis. J Pediatr Orthop 1992;12(1):1-10
   PubMed Web of Science ®Google Scholar
• Cates JMM, Black JO, Itani DM, et al. Signal transduction pathway analysis in fibromatosis: receptor and nonreceptor tyrosine kinases. Hum Pathol 2012;43(10):1711-18
   PubMed Web of Science ®Google Scholar
• Santos GAC, Cunha IW, Rocha RM, et al. Evaluation of estrogen receptor alpha, estrogen receptor beta, progesterone receptor, and cKIT expression in desmoids tumors and their role in determining treatment options. Biosci Trends 2010;4(1):25-30
   PubMedGoogle Scholar
• Hong H, Nadesan P, Poon R, Alman BA. Testosterone regulates cell proliferation in aggressive fibromatosis (desmoid tumour). Br J Cancer 2011;104(9):1452-8
   PubMed Web of Science ®Google Scholar
• Ishizuka M, Hatori M, Dohi O, et al. Expression profiles of sex steroid receptors in desmoid tumors. Tohoku J Exp Med 2006;210(3):189-98
   PubMed Web of Science ®Google Scholar
• Monneur A, Chetaille B, Perrot D, et al. Dramatic and delayed response to Doxorubicin-dacarbazine chemotherapy of a giant desmoid tumor: case report and literature review. Case Rep Oncol 2013;6(1):127-33
   PubMedGoogle Scholar
• Lazar AJF, Tuvin D, Hajibashi S, et al. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol 2008;173(5):1518-27
   PubMed Web of Science ®Google Scholar
• Dômont J, Salas S, Lacroix L, et al. High frequency of beta-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management. Br J Cancer 2010;102(6):1032-6
   PubMed Web of Science ®Google Scholar
• Mullen JT, DeLaney TF, Rosenberg AE, et al. Beta-Catenin mutation status and outcomes in sporadic desmoid tumors. Oncologist 2013;18(9):1043-9
   PubMed Web of Science ®Google Scholar
• Van Broekhoven DLM, Verhoef C, Grünhagen DJ, et al. Prognostic value of CTNNB1 gene mutation in primary sporadic aggressive fibromatosis. Ann Surg Oncol 2014;22(5):1464-70
   PubMed Web of Science ®Google Scholar
• Aitken SJ, Presneau N, Kalimuthu S, et al. Next-generation sequencing is highly sensitive for the detection of beta-catenin mutations in desmoid-type fibromatoses. Virchows Arch 2015;467(2):203-10
   PubMed Web of Science ®Google Scholar
• Alman B, Li C, Pajerski ME, et al. Increased beta-catenin protein and somatic APC mutations in sporadic aggressive fibromatoses (desmoid tumors). Am J Pathol 1997;151(2):329-34
   PubMed Web of Science ®Google Scholar
• Tejpar S, Li C, Yu C, et al. Tcf-3 expression and beta-catenin mediated transcriptional activation in aggressive fibromatosis (desmoid tumour). Br J Cancer 2001;85(1):98-101
   PubMed Web of Science ®Google Scholar
• Colombo C, Miceli R, Lazar AJ, et al. CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent, multicenter validation study. Cancer 2013;119(20):3696-702
   PubMed Web of Science ®Google Scholar
• Flucke U, Tops BBJ, van Diest PJ, Slootweg PJ. Desmoid-type fibromatosis of the head and neck region in the paediatric population: a clinicopathological and genetic study of seven cases. Histopathology 2014;64(6):769-76
   PubMed Web of Science ®Google Scholar
• Li C, Bapat B, Alman BA. Adenomatous polyposis coli gene mutation alters proliferation through its beta-catenin-regulatory function in aggressive fibromatosis (desmoid tumor). Am J Pathol 1998;153(3):709-14
   PubMed Web of Science ®Google Scholar
• Latchford A, Volikos E, Johnson V, et al. APC mutations in FAP-associated desmoid tumours are non-random but not just right. Hum Mol Genet 2007;16(1):78-82
   PubMed Web of Science ®Google Scholar
• Robanus-Maandag E, Bosch C, Amini-Nik S, et al. Familial adenomatous polyposis-associated desmoids display significantly more genetic changes than sporadic desmoids. PLoS ONE 2011;6(9):e24354
   PubMed Web of Science ®Google Scholar
• Nieuwenhuis MH, Lefevre JH, Bülow S, et al. Family history, surgery, and APC mutation are risk factors for desmoid tumors in familial adenomatous polyposis: an international cohort study. Dis Colon Rectum 2011;54(10):1229-34
   PubMed Web of Science ®Google Scholar
• Schiessling S, Kihm M, Ganschow P, et al. Desmoid tumour biology in patients with familial adenomatous polyposis coli. Br J Surg 2013;100(5):694-703
   PubMed Web of Science ®Google Scholar
• Jung WB, Kim CW, Kim JC. Clinical characteristics and adequate treatment of familial adenomatous polyposis combined with desmoid tumors. Cancer Res Treat 2014;46(4):366-73
   PubMedGoogle Scholar
• Church J, Xhaja X, LaGuardia L, et al. Desmoids and genotype in familial adenomatous polyposis. Dis Colon Rectum 2015;58(4):444-8
   PubMed Web of Science ®Google Scholar
• Caspari R, Olschwang S, Friedl W, et al. Familial adenomatous polyposis: desmoid tumours and lack of ophthalmic lesions (CHRPE) associated with APC mutations beyond codon 1444. Hum Mol Genet 1995;4(3):337-40
   PubMed Web of Science ®Google Scholar
• Friedl W, Caspari R, Sengteller M, et al. Can APC mutation analysis contribute to therapeutic decisions in familial adenomatous polyposis? Experience from 680 FAP families. Gut 2001;48(4):515-21
   PubMed Web of Science ®Google Scholar
• Fodde R, Kuipers J, Rosenberg C, et al. Mutations in the APC tumour suppressor gene cause chromosomal instability. Nat Cell Biol 2001;3(4):433-8
   PubMed Web of Science ®Google Scholar
• Salas S, Chibon F, Noguchi T, et al. Molecular characterization by array comparative genomic hybridization and DNA sequencing of 194 desmoid tumors. Genes Chromosomes Cancer 2010;49(6):560-8
   PubMed Web of Science ®Google Scholar
• Schwarz-Romond T. The ankyrin repeat protein Diversin recruits Casein kinase Iepsilon to the beta -catenin degradation complex and acts in both canonical Wnt and Wnt/JNK signaling. Genes Dev 2002;16(16):2073-84
   PubMed Web of Science ®Google Scholar
• Hartley JE, Church JM, Gupta S, et al. Significance of incidental desmoids identified during surgery for familial adenomatous polyposis. Dis Colon Rectum 2004;47(3):334-8. discussion 339–40
   PubMed Web of Science ®Google Scholar
• Fiore M, Rimareix F, Mariani L, et al. Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. Ann Surg Oncol 2009;16(9):2587-93
   PubMed Web of Science ®Google Scholar
• Barbier O, Anract P, Pluot E, et al. Primary or recurring extra-abdominal desmoid fibromatosis: assessment of treatment by observation only. Orthop Traumatol Surg Res 2010;96(8):884-9
   PubMed Web of Science ®Google Scholar
• Salas S, Dufresne A, Bui B, et al. Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: A wait-and-see policy according to tumor presentation. J Clin Oncol 2011;29(26):3553-8
   PubMed Web of Science ®Google Scholar
• Briand S, Barbier O, Biau D, et al. Wait-and-see policy as a first-line management for extra-abdominal desmoid tumors. J Bone Joint Surg Am 2014;96(8):631-8
   PubMed Web of Science ®Google Scholar
• Soft tissue and visceral sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014;25(Suppl 3):iii102-12
   PubMed Web of Science ®Google Scholar
• Kasper B, Baumgarten C, Bonvalot S, et al. Management of sporadic desmoid-type fibromatosis: a European consensus approach based on patients’ and professionals expertise - a sarcoma patients EuroNet and European organisation for research and treatment of cancer/soft tissue and bone sarcoma group. Eur J Cancer 2015;51(2):127-36
   PubMed Web of Science ®Google Scholar
• Eastley NC, Hennig IM, Esler CP, Ashford RU. Nationwide trends in the current management of desmoid (Aggressive) fibromatosis. Clin Oncol 2015;27(6):362-8
   Web of Science ®Google Scholar
• Bonvalot S, Eldweny H, Haddad V, et al. Extra-abdominal primary fibromatosis: Aggressive management could be avoided in a subgroup of patients. Eur J Surg Oncol 2008;34(4):462-8
   PubMed Web of Science ®Google Scholar
• Tanaka K, Yoshikawa R, Yanagi H, et al. Regression of sporadic intra-abdominal desmoid tumour following administration of non-steroidal anti-inflammatory drug. World J Surg Oncol 2008;6:17
   PubMed Web of Science ®Google Scholar
• Peripheral primitive fibromatosis (WS-RT Fibro). Available from: https://clinicaltrials.gov/ct2/show/NCT01801176
   Google Scholar
• Peng PD, Hyder O, Mavros MN, et al. Management and recurrence patterns of desmoids tumors: a multi-institutional analysis of 211 patients. Ann Surg Oncol 2012;19(13):4036-42
   PubMed Web of Science ®Google Scholar
• Mullen JT, Delaney TF, Kobayashi WK, et al. Desmoid tumor: analysis of prognostic factors and outcomes in a surgical series. Ann Surg Oncol 2012;19(13):4028-35
   PubMed Web of Science ®Google Scholar
• Crago AM, Denton B, Salas S, et al. A prognostic nomogram for prediction of recurrence in desmoid fibromatosis. Ann Surg 2013;258(2):347-53
   PubMed Web of Science ®Google Scholar
• Huang K, Wang CM, Chen JG, et al. Prognostic factors influencing event-free survival and treatments in desmoid-type fibromatosis: analysis from a large institution. Am J Surg 2014;207(6):847-54
   PubMed Web of Science ®Google Scholar
• Zeng W-G, Zhou Z-X, Liang J-W, et al. Prognostic factors for desmoid tumor: a surgical series of 233 patients at a single institution. Tumour Biol 2014;35(8):7513-21
   PubMed Web of Science ®Google Scholar
• Cates JMM, Stricker TP. Surgical resection margins in desmoid-type fibromatosis: a critical reassessment. Am J Surg Pathol 2014;38(12):1707-14
   PubMed Web of Science ®Google Scholar
• He XDD, Zhang YBB, Wang L, et al. Prognostic factors for the recurrence of sporadic desmoid-type fibromatosis after macroscopically complete resection: Analysis of 114 patients at a single institution. Eur J Surg Oncol 2015;1-7
   PubMed Web of Science ®Google Scholar
• McDougall A, McGarrity G. Extra-abdominal desmoid tumours. J Bone Joint Surg Br 1979;61-B(3):373-7
   PubMed Web of Science ®Google Scholar
• Serpell JW, Paddle-Ledinek JE, Johnson WR. Modification of growth of desmoid tumours in tissue culture by anti-oestrogenic substances: a preliminary report. Aust N Z J Surg 1996;66(7):457-63
   PubMedGoogle Scholar
• Cates JMM. Pregnancy does not increase the local recurrence rate after surgical resection of desmoid-type fibromatosis. Int J Clin Oncol 2014;20(3):617-22
   PubMed Web of Science ®Google Scholar
• Fiore M, Coppola S, Cannell AJ, et al. Desmoid-type fibromatosis and pregnancy: a multi-institutional analysis of recurrence and obstetric risk. Ann Surg 2014;259(5):973-8
   PubMed Web of Science ®Google Scholar
• Castellazzi G, Vanel D, Le Cesne A, et al. Can the MRI signal of aggressive fibromatosis be used to predict its behavior? Eur J Radiol 2009;69:222-9
   PubMed Web of Science ®Google Scholar
• Bhandari S, Taylor NJ, Sinha A, et al. Can Combined 18F-FDG-PET and Dynamic Contrast-Enhanced MRI Predict Behavior of Desmoid Tumors in Patients With Familial Adenomatous Polyposis? Dis Colon Rectum 2012;55:1032-7
   PubMed Web of Science ®Google Scholar
• Salas S, Brulard C, Terrier P, et al. Gene expression profiling of desmoid tumors by cDNA microarrays and correlation with Progression-Free survival. Clin Cancer Res 2015;21(18):4194-200
   PubMed Web of Science ®Google Scholar
• Dufresne A, Paturel M, Alberti L, et al. Prediction of desmoid tumor progression using miRNA expression profiling. Cancer Sci 2015;106(5):650-5
   PubMed Web of Science ®Google Scholar
• Church J, Berk T, Boman BM, et al. Staging intra-abdominal desmoid tumors in familial adenomatous polyposis: a search for a uniform approach to a troubling disease. Dis Colon Rectum 2005;48:1528-34
   PubMed Web of Science ®Google Scholar
• Church J, Lynch C, Neary P, et al. A desmoid tumor-staging system separates patients with intra-abdominal, familial adenomatous polyposis-associated desmoid disease by behavior and prognosis. Dis Colon Rectum 2008;51:897-901
   PubMed Web of Science ®Google Scholar
• Joglekar SB, Rose PS, Sim F, et al. Current perspectives on desmoid tumors: The mayo clinic approach. Cancers (Basel) 2011;3:3143-55
   PubMedGoogle Scholar
• Bonvalot S, Desai A, Coppola S, et al. The treatment of desmoid tumors: A stepwise clinical approach. Ann Oncol 2012;23(Suppl 10):x158-66
   PubMed Web of Science ®Google Scholar
• Gronchi A, Colombo C, Le Péchoux C, et al. Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm–a position paper from the Italian and the French Sarcoma Group. Ann Oncol 2014;25(3):578-83
   PubMed Web of Science ®Google Scholar
• Gronchi A, Casali PG, Mariani L, et al. Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution. J Clin Oncol 2003;21(7):1390-7
   PubMed Web of Science ®Google Scholar
• Stoeckle E, Coindre JM, Longy M, et al. A critical analysis of treatment strategies in desmoid tumours: a review of a series of 106 cases. Eur J Surg Oncol 2009;35(2):129-34
   PubMed Web of Science ®Google Scholar
• Cates JMM. Prognostic factors for second recurrence after surgical resection of recurrent desmoid-type fibromatosis. Pathol Oncol Res 2015;21(4):1085-90
   PubMed Web of Science ®Google Scholar
• Campos FG, Martinez CAR, Novaes M, et al. Desmoid tumors: clinical features and outcome of an unpredictable and challenging manifestation of familial adenomatous polyposis. Fam Cancer 2015;14(2):211-19
   PubMed Web of Science ®Google Scholar
• Wu C, Amini-Nik S, Nik-Amini S, et al. Aggressive fibromatosis (desmoid tumor) is derived from mesenchymal progenitor cells. Cancer Res 2010;70(19):7690-8
   PubMed Web of Science ®Google Scholar
• Carothers AM, Rizvi H, Hasson RM, et al. Mesenchymal stromal cell mutations and wound healing contribute to the etiology of desmoid tumors. Cancer Res 2012;72(1):346-55
   PubMed Web of Science ®Google Scholar
• Church McGannon Ozuner The clinical course of intra-abdominal desmoid tumours in patients with familial adenomatous polyposis. Colorectal Dis 1999;1(3):168-73
   PubMedGoogle Scholar
• Desurmont T, Lefèvre JH, Shields C, et al. Desmoid tumour in familial adenomatous polyposis patients: responses to treatments. Fam Cancer 2015;14(1):31-9
   PubMed Web of Science ®Google Scholar
• Prodinger PM, Rechl H, Keller M, et al. Surgical resection and radiation therapy of desmoid tumours of the extremities: results of a supra-regional tumour centre. Int Orthop 2013;37(10):1987-93
   PubMed Web of Science ®Google Scholar
• Keus RB, Nout RA, Blay J-Y, et al. Results of a phase II pilot study of moderate dose radiotherapy for inoperable desmoid-type fibromatosis–an EORTC STBSG and ROG study (EORTC 62991-22998). Ann Oncol 2013;24(10):2672-6
   PubMed Web of Science ®Google Scholar
• De Camargo VP, Keohan ML, D’Adamo DR, et al. Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor). Cancer 2010;116(9):2258-65
   PubMed Web of Science ®Google Scholar
• Skapek SX, Ferguson WS, Granowetter L, et al. Vinblastine and methotrexate for desmoid fibromatosis in children: results of a pediatric oncology group Phase II Trial. J Clin Oncol 2007;25(5):501-6
   PubMed Web of Science ®Google Scholar
• Gega M, Yanagi H, Yoshikawa R, et al. Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis. J Clin Oncol 2006;24(1):102-5
   PubMed Web of Science ®Google Scholar
• Garbay D, Le Cesne A, Penel N, et al. Chemotherapy in patients with desmoid tumors: a study from the French sarcoma group (FSG). Ann Oncol 2012;23(1):182-6
   PubMed Web of Science ®Google Scholar
• Wehl G, Rossler J, Otten JE, et al. Response of Progressive Fibromatosis to Therapy with Liposomal Doxorubicin. Onkologie 2004;27(6):552-6
   PubMed Web of Science ®Google Scholar
• Constantinidou A, Jones RL, Scurr M, et al. Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis. Eur J Cancer 2009;45(17):2930-4
   PubMed Web of Science ®Google Scholar
• Constantinidou A, Jones RL, Scurr M, et al. Advanced aggressive fibromatosis: Effective palliation with chemotherapy. Acta Oncol 2011;50(3):455-61
   PubMed Web of Science ®Google Scholar
• Bonvalot S, Rimareix F, Causeret S, et al. Hyperthermic isolated limb perfusion in locally advanced soft tissue sarcoma and progressive desmoid-type fibromatosis with TNF 1 mg and melphalan (T1-M HILP) is safe and efficient. Ann Surg Oncol 2009;16(12):3350-7
   PubMed Web of Science ®Google Scholar
• Van Broekhoven DLM, Deroose JP, Bonvalot S, et al. Isolated limb perfusion using tumour necrosis factor α and melphalan in patients with advanced aggressive fibromatosis. Br J Surg 2014;101(13):1674-80
   PubMed Web of Science ®Google Scholar
• Kujak JL, Liu PT, Johnson GB, Callstrom MR. Early experience with percutaneous cryoablation of extra-abdominal desmoid tumors. Skeletal Radiol 2010;39(2):175-82
   PubMed Web of Science ®Google Scholar
• Cornelis F, Italiano A, Al-Ammari S, et al. Successful iterative percutaneous cryoablation of multiple extraabdominal desmoid tumors in a patient with Gardner syndrome. J Vasc Interv Radiol 2012;23(8):1101-3
   PubMed Web of Science ®Google Scholar
• Havez M, Lippa N, Al-Ammari S, et al. Percutaneous image-guided cryoablation in inoperable extra-abdominal desmoid tumors: a study of tolerability and efficacy. Cardiovasc Intervent Radiol 2014;37(6):1500-6
   PubMed Web of Science ®Google Scholar
• Bocale D, Rotelli MT, Cavallini A, Altomare DF. Anti-oestrogen therapy in the treatment of desmoid tumours: a systematic review. Colorectal Dis 2011;13(12):e388-95
   PubMed Web of Science ®Google Scholar
• Skapek SX, Anderson JR, Hill DA, et al. Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a Children’s Oncology Group (COG) phase II study. Pediatr Blood Cancer 2013;60(7):1108-12
   PubMed Web of Science ®Google Scholar
• Nishida Y, Tsukushi S, Shido Y, et al. Transition of treatment for patients with extra-abdominal desmoid tumors: Nagoya University modality. cancers (Basel) 2012;4(4):88-99
   PubMedGoogle Scholar
• Hamada S, Futamura N, Ikuta K, et al. CTNNB1 S45F mutation predicts poor efficacy of meloxicam treatment for desmoid tumors: a pilot study. PLoS ONE 2014;9(5):e96391
   PubMed Web of Science ®Google Scholar
• Heinrich MC, McArthur GA, Demetri GD, et al. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol 2006;24(7):1195-203
   PubMed Web of Science ®Google Scholar
• Chugh R, Wathen JK, Patel SR, et al. Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma alliance for research through collaboration (SARC) trial. Clin Cancer Res 2010;16(19):4884-91
   PubMed Web of Science ®Google Scholar
• Penel N, Le Cesne A, Bui BN, et al. Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. Ann Oncol 2011;22(2):452-7
   PubMed Web of Science ®Google Scholar
• Study to evaluate imatinib in desmoid tumors. Available from: https://clinicaltrials.gov/ct2/show/NCT01137916
   Google Scholar
• Kasper B. Systemic treatment approaches for sporadic desmoid-type fibromatosis: scarce evidence and recommendations. Oncol Res Treat 2015;38(5):244-8
   Google Scholar
• Dufresne A, Alberti L, Brahmi M, et al. Impact of KIT exon 10 M541L allelic variant on the response to imatinib in aggressive fibromatosis: analysis of the desminib series by competitive allele specific Taqman PCR technology. BMC Cancer 2014;14:632
   PubMed Web of Science ®Google Scholar
• Jo J-C, Hong YS, Kim K-P, et al. A prospective multicenter phase II study of sunitinib in patients with advanced aggressive fibromatosis. Invest New Drugs 2014;32(2):369-76
   PubMed Web of Science ®Google Scholar
• PAZOPANIB efficacy and tolerance in desmoids tumors (DESMOPAZ). Available from: https://clinicaltrials.gov/ct2/show/NCT01876082
   Google Scholar
• Martin-Liberal J, Benson C, McCarty H, et al. Pazopanib is an active treatment in desmoid tumour/aggressive fibromatosis. Clin Sarcoma Res 2013;3(1):13
   Google Scholar
• Gounder MM, Lefkowitz RA, Keohan ML, et al. Activity of Sorafenib against desmoid tumor/deep fibromatosis. Clin Cancer Res 2011;17(12):4082-90
   PubMed Web of Science ®Google Scholar
• Sorafenib Tosylate in treating patients with desmoid tumors or aggressive fibromatosis. Available from: https://clinicaltrials.gov/ct2/show/NCT02066181
   Google Scholar
• Messersmith WA, Shapiro GI, Cleary JM, et al. A Phase I, dose-finding study in patients with advanced solid malignancies of the oral γ-secretase inhibitor PF-03084014. Clin Cancer Res 2015;21(1):60-7
   PubMed Web of Science ®Google Scholar
• Phase II Trial of the gamma-secretase inhibitor pf-03084014 in adults with desmoid tumors/aggressive fibromatosis. Available from: https://clinicaltrials.gov/ct2/show/NCT01981551
   Google Scholar
• A pilot study evaluating the use of mtor inhibitor sirolimus in children and young adults with desmoid-type fibromatosis. Available from: https://clinicaltrials.gov/ct2/show/NCT01265030
   Google Scholar
• Fujishita T, Aoki K, Lane HA, et al. Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice. Proc Natl Acad Sci USA 2008;105(36):13544-9
   PubMed Web of Science ®Google Scholar
• A dose escalation study of omp-54f28 in subjects with solid tumors. Available from: https://clinicaltrials.gov/ct2/show/NCT01608867
   Google Scholar
• Le PN, McDermott JD, Jimeno A. Targeting the Wnt pathway in human cancers: Therapeutic targeting with a focus on OMP-54F28. Pharmacol Ther 2015;146:1-11
   PubMed Web of Science ®Google Scholar
• Poon R, Hong H, Wei X, et al. A high throughput screen identifies Nefopam as targeting cell proliferation in beta-catenin driven neoplastic and reactive fibroproliferative disorders. PLoS One 2012;7(5):e37940
   PubMed Web of Science ®Google Scholar
• Miyaki M, Konishi M, Kikuchi-Yanoshita R, et al. Coexistence of somatic and germ-line mutations of APC gene in desmoid tumors from patients with familial adenomatous polyposis. Cancer Res 1993;53(21):5079-82
   PubMed Web of Science ®Google Scholar
• Barton-Davis ER, Cordier L, Shoturma DI, et al. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest 1999;104(4):375-81
   PubMed Web of Science ®Google Scholar
• Bordeira-Carriço R, Pêgo AP, Santos M, Oliveira C. Cancer syndromes and therapy by stop-codon readthrough. Trends Mol Med 2012;18(11):667-78
   PubMed Web of Science ®Google Scholar
• Bidou L, Allamand V, Rousset J-P, Namy O. Sense from nonsense: therapies for premature stop codon diseases. Trends Mol Med 2012;18(11):679-88
   PubMed Web of Science ®Google Scholar
• Floquet C, Deforges J, Rousset J-P, Bidou L. Rescue of non-sense mutated p53 tumor suppressor gene by aminoglycosides. Nucleic Acids Res 2011;39(8):3350-62
   PubMed Web of Science ®Google Scholar
• Zilberberg A, Lahav L, Rosin-Arbesfeld R. Restoration of APC gene function in colorectal cancer cells by aminoglycoside- and macrolide-induced read-through of premature termination codons. Gut 2010;59(4):496-507
   PubMed Web of Science ®Google Scholar
• Floquet C, Rousset J-P, Bidou L. Readthrough of premature termination codons in the adenomatous polyposis coli gene restores its biological activity in human cancer cells. PLoS One 2011;6(8):e24125
   PubMed Web of Science ®Google Scholar
• Erythromycin treatment for readthrough of apc gene stop codon mutations in familial adenomatous polyposis. Available from: https://clinicaltrials.gov/ct2/show/NCT02175914
   Google Scholar
• Brabletz T, Jung A, Reu S, et al. Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci USA 2001;98(18):10356-61
   PubMed Web of Science ®Google Scholar
• Rigaux P, Lefebvre-Kuntz D, Penel N. Pain burden in desmoid tumor patients: a survey of the French Advocacy Group SOS Desmoid. Bull Cancer 2015;102(3):213-16
   PubMed Web of Science ®Google Scholar
• Bertani E, Testori A, Chiappa A, et al. Recurrence and prognostic factors in patients with aggressive fibromatosis. the role of radical surgery and its limitations. World J Surg Oncol 2012;10:184
   PubMed Web of Science ®Google Scholar
• Sri-Ram K, Haddo O, Dannawi Z, et al. The outcome of extra-abdominal fibromatosis treated at a tertiary referral centre. Eur J Surg Oncol 2012;38(8):700-5
   PubMed Web of Science ®Google Scholar